Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374465 | 0.90 | POLB (0.44) | POLBKMT2AGAAHSD17B10KCNA3 | |
| SCHEMBL3377865 | 0.89 | POLB (0.48) | POLBKMT2AGAAHSD17B10KCNA3 | |
| SCHEMBL3373248 | 0.86 | MEN1 (0.40) | KMT2AHSD17B10HPGDMEN1KDM4E | |
| SCHEMBL3376138 | 0.86 | POLB (0.45) | POLBKMT2AGAAHSD17B10KCNA3 | |
| SCHEMBL3378396 | 0.85 | HCRTR1 (0.45) | KMT2AHPGDMEN1NPSR1ALDH1A1 | |
| SCHEMBL3377855 | 0.84 | MEN1 (0.51) | KMT2AHSD17B10HPGDSMN1; SMN2MEN1 | |
| SCHEMBL3373267 | 0.83 | TSHR (0.54) | KMT2AHPGDSMN1; SMN2MEN1KDM4E | |
| SCHEMBL3377883 | 0.81 | HCRTR1 (0.41) | KMT2ATP53HPGDSMN1; SMN2MEN1 | |
| SCHEMBL3377960 | 0.80 | MEN1 (0.41) | POLBKMT2AHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL3376469 | 0.80 | ALDH1A1 (0.42) | KMT2AHPGDSMN1; SMN2MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517886-B1 | NOVEL PHTHALAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-11-10 | — | — | EP | disclosed |
| US-7132455-B2 | Phthalamide derivatives | BAYER CROPSCIENCE AG (DE) | 2006-11-07 | — | — | US | disclosed |
| US-20060035967-A1 | Novel phthalamide derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| EP-1517886-A1 | NOVEL PHTHALAMIDE DERIVATIVES | Bayer CropScience AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000796-A1 | NOVEL PHTHALAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035967-A1 | Novel phthalamide derivatives | HDAC1, HDAC2, CRY1 | POLB 4159/4885KMT2A 102/4885GAA 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.